particular health condition(s) or problem(s) being prevented
Conditions
Interventions
Children patients who have experienced Rabies WHO category II exposure,Children patients who have experienced Rabies WHO category III exposure
Prevention,Prevention
patients with WHO category II,patients with WHO category III
Sponsors
Liaoning Cheng Da Biotechnology Company in China.
The Thai Red Cross Society
Eligibility
Sex/Gender
All
Age
1 Years to 15 Years
Inclusion criteria
Inclusion criteria: All participants are included in the study will be evaluated by a physician prior to enrollment in the study. Participants or patients meet the inclusion criteria if they are 1-15 years and give signed informed consent from their parents, willing to participate in this study and be able to receive the vaccination and collect blood sample as the study plan.
Exclusion criteria
Exclusion criteria: They will be excluded if they have prior history of rabies vaccination or any equine/human serum administration such as snake antivenom and tetanus antiserum or vaccine allergy, Persons who have immunosuppressive conditions such as known HIV infection, transplantation, chronic renal failure, receiving of steroid or immunosuppressive drugs were excluded, person received anti-malarial drugs within the previous two months or any blood products within previous three months were excluded. Urine pregnancy test must be done in all female adolescents to exclude the pregnancy in first visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rabies neutralizing antibody (Nab) after using of the TRC-ID regimen with CPRV with or without RIG 1 year Rabies Nab titers were measured by using the rapid fluorescent focus inhibition test (RFFIT) | — |
Secondary
| Measure | Time frame |
|---|---|
| safety 1 year Record form for any locall reactions at the injection site (pain, itiching, warm, swellling) and sys | — |
Contacts
Public ContactManeerat Benjavongkulchai
QSMI, The Thai Red Cross Society
Outcome results
None listed